Detalhe da pesquisa
1.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1131-1143, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162177
2.
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
Haematologica
; 107(11): 2685-2697, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484662
3.
Deciphering the complexity of human non-coding promoter-proximal transcriptome.
Bioinformatics
; 35(15): 2529-2534, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30535182
4.
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma.
Hematol Oncol
; 42(3): e3275, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38650582
5.
Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription.
RNA Biol
; 14(12): 1742-1755, 2017 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28805496
6.
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease.
Haematologica
; 104(6): e256-e259, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30545928
7.
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Mol Cancer Ther
; 23(3): 368-380, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052765
8.
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells.
EMBO J
; 28(12): 1708-19, 2009 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19461583
9.
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Am J Cancer Res
; 13(5): 2076-2086, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37293172
10.
Tau protein modulates an epigenetic mechanism of cellular senescence in human SH-SY5Y neuroblastoma cells.
Front Cell Dev Biol
; 11: 1232963, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37842084
11.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Cancer Res Commun
; 3(4): 576-591, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37066023
12.
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
bioRxiv
; 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38014209
13.
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
bioRxiv
; 2023 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711490
14.
Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades.
Cancers (Basel)
; 14(8)2022 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454885
15.
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
EJHaem
; 3(3): 764-774, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051080
16.
LncRNAs and Available Databases.
Methods Mol Biol
; 2348: 3-26, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34160796
17.
Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.
Noncoding RNA
; 7(2)2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33923420
18.
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Explor Target Antitumor Ther
; 2(6): 586-601, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046113
19.
ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
J Exp Clin Cancer Res
; 40(1): 357, 2021 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763718
20.
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.
Cancers (Basel)
; 12(7)2020 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32679859